论文部分内容阅读
目的:评价苯磺酸左旋氨氯地平与厄贝沙坦联用对高血压伴冠心病患者的临床疗效。方法:选取2012年11月—2015年8月间诊治的高血压伴冠心病患者95例,按照随机数字表法将患者分为治疗组(48例)和对照组(47例);治疗组患者均给予苯磺酸左旋氨氯地平片与厄贝沙坦分散片联用治疗,对照组患者均给予厄贝沙坦分散片治疗,比较两组患者治疗后的血压及血脂各指标值、总有效率及不良反应的发生率。结果:治疗后治疗组患者的收缩压、舒张压值明显低于治疗前(P<0.05);对照组患者的收缩压、舒张压值明显低于治疗前(P<0.05),治疗组患者的收缩压、舒张压值明显低于对照组(P<0.05);治疗后治疗组患者的三酰甘油(TG)、总胆固醇(TC)、低密度脂蛋白胆固醇(LDL-C)和高密度脂蛋白胆固醇(HDL-C)值明显低于治疗前(P<0.05);对照组患者的TG、TC、LDL-C和HDL-C值明显低于治疗前(P<0.05);治疗组患者的TG、TC、LDL-C和HDL-C值明显低于对照组(P<0.05);治疗组患者临床治疗总有效率明显高于对照组(P<0.05);两组患者治疗期间不良反应发生率经比较其差异无统计学意义(P>0.05)。结论:苯磺酸左旋氨氯地平与厄贝沙坦联用治疗较单用厄贝沙坦对高血压伴冠心病患者的临床疗效好,其血压及血脂各指标值易控制,且无不良反应症状的发生。
Objective: To evaluate the clinical efficacy of levamlodipine besylate combined with irbesartan on patients with hypertension and coronary heart disease. Methods: A total of 95 hypertensive patients with coronary heart disease (CHD) diagnosed and treated from November 2012 to August 2015 were selected and divided into treatment group (48 cases) and control group (47 cases) according to random number table method. Patients in treatment group Were given levamisodipine besylate tablets and irbesartan dispersible tablets combined treatment, patients in the control group were treated with irbesartan dispersible tablets, compared two groups of patients after treatment of blood pressure and lipid values of the indicators, there are always Efficiency and incidence of adverse reactions. Results: The systolic blood pressure and diastolic blood pressure of the treatment group were significantly lower than those before treatment (P <0.05); the systolic blood pressure and diastolic blood pressure of the control group were significantly lower than those before treatment (P <0.05) Systolic blood pressure and diastolic blood pressure were significantly lower than those in the control group (P <0.05). After treatment, the triglyceride (TG), total cholesterol (TC), low density lipoprotein cholesterol (LDL-C) The levels of HDL-C were significantly lower than those before treatment (P <0.05). The levels of TG, TC, LDL-C and HDL-C in control group were significantly lower than those before treatment (P <0.05) TG, TC, LDL-C and HDL-C in the treatment group were significantly lower than those in the control group (P <0.05). The total effective rate of clinical treatment in the treatment group was significantly higher than that in the control group (P <0.05) Rate after the difference was not statistically significant (P> 0.05). Conclusion: L-amlodipine besylate combined with irbesartan is more effective than irbesartan alone in patients with hypertension and coronary heart disease, and the indexes of blood pressure and blood lipids are easy to control without adverse reactions Symptoms happen.